SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending intensely right now ahead of its earnings report, with community focus on its massive AI infrastructure investments and significant debt levels. Investors are debating if robust cloud growth and demand for AI compute will offset concerns over capital expenditure and conflicting reports about the status of a major data center expansion deal.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and strong delivery guidance, fueling community excitement over a potential short squeeze and comparisons to past EV growth rallies, despite facing immediate price resistance.

Hydrograph Clean Power, Inc. engages in the research, development, marketing and commercialization of patented technology to produce pristine graphene, graphene derivatives and services. The company was founded by Harold Charles Davidson on June 26, 2017 and is headquartered in Vancouver, Canada.

Hydrograph Clean Power Inc

HGRAF is surging amid regulatory clearances for its ultra-pure graphene in key markets and anticipation of its Austin facility launch and NASDAQ uplisting, with the community actively debating its potential to revolutionize industries and secure major commercial contracts.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following impressive Q4 financial results, which showcased strong revenue growth from its rare disease drug MIPLYFFA and a significant shift to profitability, sparking community discussions about its re-valuation as a commercial-stage enterprise. Anticipation for European approval of MIPLYFFA, coupled with increased analyst price targets and high trading volume, is fueling speculation among investors.

CitroTech, Inc. is an integrated environmental service company, which engages in the provision of field services, remediation transportation, and EHS compliance services. It also offers on-site technical services, on-site and off-site treatment for hazardous and non-hazardous waste. The company was founded on March 14, 1990 and is headquartered in Cheyenne, WY.

CitroTech Inc.

CitroTech Inc. (CITR) is generating strong trading momentum and community buzz due to its presentation at the iAccess Alpha conference, showcasing its differentiated fire-retardant wood technology, with its low share float driving speculation of a significant re-rating if commercial traction continues.

Polaryx Therapeutics, Inc. engages in the manufacturing of biotechnology products. Its pipeline of products includes PLX-100, PLX-200, and PLX-300. The company was founded by Hahn-Jun Lee on August 22, 2014 and is headquartered in Paramus, NJ.

Polaryx Therapeutics Inc.

Polaryx Therapeutics (PLYX), a clinical-stage biotech focusing on rare diseases, is highly volatile following its announcement of a CRO selection for its PLX-200 Phase 2 trial, sparking intense community speculation around short squeeze potential given its low float and direct listing structure.

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

CRISPR Therapeutics is trending due to widespread community frustration and confusion surrounding its announced proposed convertible senior notes offering, with many questioning management's strategic intentions for raising capital despite existing substantial cash reserves and speculating on possible institutional arbitrage plays.

Kraken Robotics, Inc. engages in the design, manufacture, and sale of software-centric sensors, subsea batteries, thrusters and underwater robotic systems. It operates through the following geographical segments: Asia Pacific, Europe, Middle East and Africa, North America, and Other. The company was founded on May 14, 2008, and is headquartered in Mt. Pearl, Canada.

Kraken Robotics Inc

Kraken Robotics is making new all-time highs and fueling bullish community sentiment following its transformative acquisition of Covelya Group, integrating key subsea technologies to become a dominant player in underwater defense and marine infrastructure. Investors are actively discussing its strategic expansion, crucial partnerships, and potential future NASDAQ uplisting.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is trending amidst heightened geopolitical anxiety following reports of Iran preparing to deploy naval mines in the Strait of Hormuz, which immediately impacts oil prices and global shipping. This development is intensifying market volatility and community debate, especially given the administration's conflicting messages on the conflict's status.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

BioNTech is trending after releasing disappointing future revenue guidance and announcing that its co-founders will depart to launch a new biotech venture. This has ignited intense community debate, with some viewing it as a clear signal of underlying issues while others see an emotional overreaction and a potential buying opportunity for its oncology pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DLD Asset Management LP Acquires New Position in Spyre Therapeutics, Inc. $SYRE

DLD Asset Management LP bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 3rd quarter, according to its most recent disclosure with the SEC. The...

Spyre Therapeutics, Inc. $SYRE Shares Sold by TD Asset Management Inc

TD Asset Management Inc decreased its position in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 36.5% in the third quarter, according to its most recent Form 13F filing with the SEC. The...

Cameron Turtle Sells 15,000 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the firm's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of...

Scott Burrows Sells 2,500 Shares of Spyre Therapeutics (NASDAQ:SYRE) Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 2,500 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $40.65...

Spyre Therapeutics (NASDAQ:SYRE) CEO Sells $632,850.00 in Stock

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of the company's stock in a transaction on Monday, March 2nd. The stock was sold at an average price of...

Spyre Therapeutics, Inc. (NASDAQ:SYRE) Given Consensus Rating of "Buy" by Brokerages

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has earned an average rating of "Buy" from the ten ratings firms that are covering the company, Marketbeat reports. One equities research...

Spyre Therapeutics (NASDAQ:SYRE) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded Spyre Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday...

Wells Fargo & Company Issues Positive Forecast for Spyre Therapeutics (NASDAQ:SYRE) Stock Price

Wells Fargo & Company raised their price target on shares of Spyre Therapeutics from $40.00 to $50.00 and gave the company an "overweight" rating in a report on Friday...

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Time to Buy?

Spyre Therapeutics (NASDAQ:SYRE) Trading Up 6.3% - Here's Why...

Spyre Therapeutics (NASDAQ:SYRE) Receives Buy Rating from BTIG Research

BTIG Research reissued a "buy" rating and set a $70.00 price objective on shares of Spyre Therapeutics in a report on Friday...

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

Current Price	$41.35
Prev Close	$41.07
Open	$41.33
Dividend Yield	0.00%
50-Day Moving Average	$35.27
Beta	1.71
Avg. Volume	771,183.17
PE Ratio	-19.76

52-Week High	$45.76
52-Week Low	$10.91
Market Capitalization	$3.23B
EPS (Annual)	-$1.98
Price to Book	5.74
Revenue Per Employee	$0.00

SYRE
Aeglea BioTherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SYRE News

SYREAeglea BioTherapeutics Inc